Why is your weight loss slowing down on Wegovy?

Is slowing weight loss on Wegovy normal, or a sign something is wrong?

Almost everyone experiences a deceleration. The first eight to twelve weeks of Wegovy treatment tend to produce the sharpest losses because the initial appetite suppression is strongest and the body has not yet compensated. After that, several things happen at once. Your body weight falls, so your basal metabolic energy needs fall with it, meaning the same eating pattern that produced a 1.5 lb weekly loss at the start now produces less. Meanwhile, the way semaglutide slows digestion becomes familiar to your gut, and the novelty of reduced hunger can wear off slightly as your brain recalibrates its set point.

The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. The trajectory of that loss is not a straight line: most of it occurs in the first 20 to 28 weeks, with a gradual flattening thereafter. So if your loss has slowed six months in, you are following exactly the pattern the clinical trial participants followed. That is reassuring, not alarming.

Where it becomes clinically relevant is if loss has stopped entirely for more than four to six weeks, or if you have not reached 5% total weight loss after six months at the highest dose you can tolerate. NICE's appraisal of semaglutide (TA875) explicitly includes a review point at that six-month mark, recommending that continuation be assessed if the 5% threshold has not been met. That is a conversation to have with your prescriber, not a reason to stop without guidance.

Could it be something other than the medicine itself?

Yes, and this is where the clinical review matters most. Several factors unrelated to semaglutide's pharmacology can slow progress:

Calorie creep. Appetite suppression is powerful early on, but it is not absolute. Portion sizes quietly expand again, or high-calorie drinks and snacks slip back in without registering as meals. A brief food diary (even three days' worth) often surprises people.

Reduced movement. Weight loss itself can cause fatigue, and some people inadvertently move less as the months go on. The total energy-out side of the equation matters alongside what semaglutide does to energy-in. If you want to read more about whether Wegovy affects your metabolic rate directly, that question has a specific answer worth knowing.

Muscle loss. GLP-1 medicines reduce overall intake significantly. Without adequate protein and some resistance activity, a proportion of the weight lost can come from lean mass rather than fat. Less muscle means a lower resting metabolic rate, which compounds the plateau.

Dose. If you are still on an early titration dose (0.5 mg or 1.0 mg) the plateau may resolve when you reach 1.7 mg or 2.4 mg, or at the newer 7.2 mg maintenance dose approved by the MHRA in early 2026. Your prescriber decides when and whether a dose change is appropriate; it is not something to adjust independently.

What can actually restart progress?

Practical steps fall into three categories. First, revisit the lifestyle piece honestly. Protein at every meal helps preserve lean muscle and keeps you fuller; the NHS Better Health programme has straightforward guidance on building a sustainable deficit alongside medication. Strength-based activity two to three times a week makes a measurable difference to body composition even when the scale barely moves.

Second, talk to your prescriber before changing anything about your dose or injection timing. If you are buying through a regulated service, that conversation should be straightforward; if you are sourcing treatment without ongoing clinical access, a plateau is a good prompt to reassess the setup. For context on how Wegovy is priced as part of a private service, the cost page covers what clinical review should include.

Third, reframe the measure. The scale is one data point. Waist circumference, blood pressure, energy levels and how clothes fit all track progress that body weight misses. A month with no scale movement but a 2 cm reduction in waist size is still a month of meaningful change.

If you are finding that losing weight slowly on Wegovy is becoming a pattern rather than a phase, a structured clinical review (covering dose, diet, activity and whether semaglutide is still the right medicine for your situation) is the most useful next step. Our prescribers at nume review every repeat order before it is dispensed, which means there is a natural checkpoint built in.

When should you actually be concerned?

A slowing pace is normal. A complete stop needs attention. Contact your prescriber or GP promptly if weight loss has halted entirely for more than six weeks, if you are experiencing significant side effects that are affecting your intake (persistent vomiting or severe nausea beyond the usual settling-in period), or if you have developed any new symptoms since starting treatment. Severe, persistent abdominal pain that spreads toward the back is a symptom the MHRA has specifically flagged in connection with GLP-1 medicines, seek same-day medical help if that occurs, not a message to your online pharmacy.

For a broader picture of how the medicine works and what to expect across the full treatment period, the Wegovy weight loss overview covers the clinical evidence in more detail. And if you have questions specific to your own situation, the free consultation at nume connects you with a GPhC-registered prescriber who reads your answers the same day, a real clinician, not an automated system.